Takeaway: From Mr. Pim's seat, he sees and must navigate many of the topics we write about daily: nurse staffing, Rx supply chain, RPM, RCM, etc.

Overview

We’re excited to host a discussion and Q&A featuring Brit Pim, CEO of Healix, a national provider of infusion management services with broad senior management experience that includes over a decade at Express Scripts. Hedgeye Health Care sector head Tom Tobin will moderate the discussion, which we expect to cover topics including, but not limited to the disruption caused by COVID-19 at the practice level (infectious disease, allergy/immunology & pulmonology, and other specialties like GI, neurology, and rheumatology), staffing costs and challenges, COVID Monoclonals ($LLY and $REGN), the "rebate rule" and most favored nation drug pricing model, home infusion & remote monitoring, and more!

We continue to track labor data closely as it informs our tracker(s) and $AMN model, as well as other data that relates to the #reopening/recovery of in-person care. We think there are some very interesting read-throughs to be gleaned from a discussion & Q&A with Brit on nurse supply/demand, orthopedics (e.g., infusions following hip and knee replacements), and other areas of focus like drug manufacturing issues, drug coupons ($GDRX), and the PBMs/government programs as we kick-off 2021.

Health Care Speaker Call | In the Trenches of Infusion Management Services

Please join us TODAY @ 2 PM ET - Add to Calendar

Subscribers: CLICK HERE for event details (includes video, dial-in info, & materials link)

About the Speaker

Health Care Call Reminder | TODAY @ 2PM ET | In the Trenches of Infusion Management Services - Brit Pim

Brit Pim is the Chief Executive Officer at Healix, LLC, a physician office infusion management company located in the greater Houston area. He is a healthcare executive with broad industry experience and an extensive background in regulated lines of business in managed care and pharmacy benefit management, including President for $30B+ Express Scripts, Government Programs Division, CEO of $3B+ Express Scripts Insurance Company, and nearly 10 years of consulting experience with Ernst & Young. While at ESI, he played key roles in integrating nearly $40B+ in acquisitions over a 12-year tenure. Brit has a proven track record of leading very large, complex, and company-wide program efforts, and he serves as an executive advisor for a private equity firm and board member and advisor to a number of healthcare services and technology companies.

Please send us your questions for Brit and Tom via .

We hope you can join us! 

Thomas Tobin
Managing Director


Twitter
LinkedIn

Justin Venneri
Director, Primary Research


Twitter
LinkedIn

William McMahon
Analyst


Twitter
LinkedIn